Compare Cart
  • Japanese
  • Korean
  • Traditional Chinese
  • Simplified Chinese
Cover Image
Market Research Report
Product code 
1031691

Neurological Biomarkers Market Research Report by Type, by Application, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
Published: | 360iResearch LLP | 197 Pages | Delivery time: 1-2 business days

Price

Back to Top
Neurological Biomarkers Market Research Report by Type, by Application, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
Published: October 5, 2021
360iResearch LLP
Content info: 197 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Global Neurological Biomarkers Market size was estimated at USD 6,110.03 million in 2020 and expected to reach USD 6,936.10 million in 2021, at a CAGR 13.85% to reach USD 13,311.72 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Neurological Biomarkers to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Genomic, Imaging, Metabolomic, and Proteomic.

Based on Application, the market was studied across Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Parkinson's Disease.

Based on End-user, the market was studied across Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neurological Biomarkers Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neurological Biomarkers Market, including AbaStar MDx, Inc., Abbott Laboratories, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Inc., Athena Diagnostics Inc, Banyan Biomarkers, Inc., Bio-Rad Laboratories, Inc., Diagenic ASA, Imagilys, Invicro. LLC., IXICO plc, Myriad RBM, Proteome Sciences Plc, Psynova Neurotech, Qiagen N.V., Quanterix Corporation, Sigma-Aldrich, Inc, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Neurological Biomarkers Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neurological Biomarkers Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neurological Biomarkers Market?
  • 4. What is the competitive strategic window for opportunities in the Global Neurological Biomarkers Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Neurological Biomarkers Market?
  • 6. What is the market share of the leading vendors in the Global Neurological Biomarkers Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Neurological Biomarkers Market?
Product Code: MRR-AD36CD897EFB

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Dynamics

  • 5.1. Introduction
  • 5.2. Drivers
    • 5.2.1. Growing prevalence of neurological disorders
    • 5.2.2. Demand for cost-effective and non-invasive diagnostic system
    • 5.2.3. Increasing preferences on early diagnosis & preventive treatment
  • 5.3. Restraints
    • 5.3.1. Stringent government regulations for approvals
  • 5.4. Opportunities
    • 5.4.1. Growing R&D focus for advancements in biomarkers
    • 5.4.2. Emerging single-cell biosensors
    • 5.4.3. Growth of low-cost clinical trials in developing countries
  • 5.5. Challenges
    • 5.5.1. Ethical problems and acceptance issues of neurological disorders

6. Neurological Biomarkers Market, by Type

  • 6.1. Introduction
  • 6.2. Genomic
  • 6.3. Imaging
  • 6.4. Metabolomic
  • 6.5. Proteomic

7. Neurological Biomarkers Market, by Application

  • 7.1. Introduction
  • 7.2. Alzheimer's Disease
  • 7.3. Autism Spectrum Disorders
  • 7.4. Multiple Sclerosis
  • 7.5. Parkinson's Disease

8. Neurological Biomarkers Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospital Laboratories
  • 8.3. Independent Clinical Diagnostic Centers
  • 8.4. Research Organizations

9. Americas Neurological Biomarkers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Neurological Biomarkers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand

11. Europe, Middle East & Africa Neurological Biomarkers Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Key Player
  • 12.4. Competitive Scenario
    • 12.4.1. Merger & Acquisition
    • 12.4.2. Agreement, Collaboration, & Partnership
    • 12.4.3. New Product Launch & Enhancement
    • 12.4.4. Investment & Funding
    • 12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. AbaStar MDx, Inc.
  • 13.2. Abbott Laboratories
  • 13.3. Acumen Pharmaceuticals
  • 13.4. Alseres Pharmaceuticals, Inc.
  • 13.5. Athena Diagnostics Inc
  • 13.6. Banyan Biomarkers, Inc.
  • 13.7. Bio-Rad Laboratories, Inc.
  • 13.8. Diagenic ASA
  • 13.9. Imagilys
  • 13.10. Invicro. LLC.
  • 13.11. IXICO plc
  • 13.12. Myriad RBM
  • 13.13. Proteome Sciences Plc
  • 13.14. Psynova Neurotech
  • 13.15. Qiagen N.V.
  • 13.16. Quanterix Corporation
  • 13.17. Sigma-Aldrich, Inc
  • 13.18. Thermo Fisher Scientific Inc.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: MARKET DYNAMICS
  • FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2026
  • FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, 2018-2026 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2026 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (%)
  • FIGURE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2026
  • FIGURE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, 2018-2026 (USD MILLION)
  • FIGURE 21. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2020 VS 2026 (%)
  • FIGURE 27. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2026
  • FIGURE 29. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 36. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 37. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 38. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 39. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 40. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 41. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 42. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 43. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 44. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 45. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 46. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 47. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 48. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 49. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 50. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 51. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 52. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 53. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 54. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 55. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 56. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 57. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 58. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 59. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 60. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 61. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 62. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 63. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 64. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 65. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 66. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 67. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2026 (USD MILLION)
  • TABLE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2026 (USD MILLION)
  • TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2026 (USD MILLION)
  • TABLE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 18. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 19. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 20. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 21. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 22. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 23. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 24. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 25. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 26. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 27. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 28. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 29. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 30. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 31. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 32. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 33. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 34. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 35. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 36. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 37. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 38. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 39. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 40. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 41. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 42. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 43. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 44. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 45. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 46. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 47. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 48. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: SCORES
  • TABLE 49. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BUSINESS STRATEGY
  • TABLE 50. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: PRODUCT SATISFACTION
  • TABLE 51. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: RANKING
  • TABLE 52. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 53. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: MERGER & ACQUISITION
  • TABLE 54. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 55. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 56. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: INVESTMENT & FUNDING
  • TABLE 57. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 58. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: LICENSE & PRICING